Long-term Control of Rheumatoid Arthritis: Oral Targeted Agent Shows Sustained Advantage Over Biologic

SELECT-PsA 1 & SELECT-PsA 2: Oral Targeted Therapy for PsA Promises Efficacy in Bio-Naïve and Refractory Patients

Control of Pathology Beyond the Skin Might Best Characterize Benefit of Psoriasis Therapy

Targeted Agent Found Better than Immunomodulator as First-Line Strategy for Relapsing Multiple Sclerosis

Extended Protection from Disability and Cognitive Dysfunction
Seen in Active SPMS

New Data Stress Large Anticoagulant Benefit in Elderly and Frail Patients with Atrial Fibrillation

ARIADNE Real-World Study: Confirming Outcomes and Wellbeing of Patients with Chronic Heart Failure

Relapsing-Remitting Multiple Sclerosis and High-efficacy Therapies

Relapsing-Remitting Multiple Sclerosis: Oral First-line Immunomodulators

VTE Prophylaxis Following Gynecologic Surgery

Next-Generation BTK Inhibitors Fulfilling Promise for CLL in Long-Term Follow-Up

Selective JAK Inhibitors Tested for Control of Psoriatic Arthritis